Related Experiment Video

Updated: Jul 16, 2025

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.4K

Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and

Yu-Ting Huang1, Yen-Ming Huang1,2, Fan-Lu Kung1

  • 1School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.

CPT: Pharmacometrics & Systems Pharmacology
|September 22, 2023
PubMed

Insights

Physiologically-based pharmacokinetic models reveal that enzyme ontogeny significantly impacts valproic acid (VPA) clearance and hepatotoxicity risk in pediatric patients. This approach aids in optimizing VPA dosing for children, addressing a critical gap in current recommendations.

Area of Science:

  • Pharmacokinetics and Drug Metabolism
  • Pediatric Pharmacology
  • Computational Modeling

Background:

  • Valproic acid (VPA) is an anticonvulsant with complex pharmacokinetics and known hepatotoxicity risks, particularly in pediatric populations.
  • Current dosing recommendations for children under 10 years old are lacking, despite higher observed risks.
  • Understanding age-related changes in drug metabolism is crucial for safe and effective VPA therapy in neonates, infants, and young children.

Purpose of the Study:

  • To develop and validate physiologically-based pharmacokinetic (PBPK) models for VPA and its toxic metabolite 4-ene-VPA.
  • To investigate the impact of drug-metabolizing enzyme ontogeny on VPA disposition and hepatotoxicity risk across pediatric age groups.
  • To predict optimal VPA dosing strategies for pediatric populations to ensure efficacy and minimize toxicity.

Main Methods:

  • Construction and simulation of PBPK models for VPA and 4-ene-VPA using adult and pediatric pharmacokinetic data.
  • Integration of information on the ontogeny of key drug-metabolizing enzymes, including CYP2C9 and UGT2B7.
  • Sensitivity analyses to assess the influence of enzyme ontogeny on VPA and 4-ene-VPA pharmacokinetics and prediction of optimal pediatric dosing.

Main Results:

  • UGT2B7 ontogeny significantly influences VPA clearance in neonates and young children.
  • CYP2C9 intrinsic clearance is a primary determinant of VPA and 4-ene-VPA exposure in infants and toddlers, correlating with higher hepatotoxicity risk.
  • The ontogeny-based PBPK models provide mechanistic insights into age-dependent VPA pharmacokinetics, outperforming traditional allometric scaling methods.

Conclusions:

  • Ontogeny-based PBPK modeling offers a robust approach for estimating VPA dosage in pediatric patients.
  • This method elucidates the mechanisms behind increased hepatotoxicity risk in young children due to 4-ene-VPA accumulation.
  • Further validation with real-world data is recommended to confirm the clinical applicability of these PBPK models for VPA therapy.

More Related Videos

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

14.8K
Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

12.7K

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
186
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
61
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
172
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
96